Edwards wins FDA approval. Edwards Lifesciences stock costs EUR 75.69 versus EUR 76.34
Published on 10/03/2026 at 12:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences announced on October 1, 2026, that the U.S. Food and Drug Administration approved its AUTUS Size-Adjustable Valve for pediatric patients requiring pulmonary valve replacement, according to an Edwards Lifesciences release. At 12:37 p.m. CEST on October 3, 2026, Edwards Lifesciences stock cost EUR 75.69 in weekend trading at Lang & Schwarz, compared with EUR 76.34 at Xetra on October 2, 2026.
Weekend trading
The Lang & Schwarz price was EUR 75.69 at 12:37 p.m. CEST on October 3, 2026. The bid was EUR 75.46 and the ask was EUR 75.92. The price was 0.85 percent below the Xetra close of EUR 76.34 on October 2, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Edwards Lifesciences stock.
The last Xetra trading day
The Xetra quote was EUR 76.34 on October 2, 2026, according to the dated market data shown by finanzen.ch. Xetra remains closed on October 3, 2026.
AUTUS approval
Edwards said the AUTUS valve is the first FDA-approved surgical pulmonary valve designed specifically for pediatric anatomy. The device can be expanded as a child grows through a minimally invasive transcatheter procedure, which the company said may reduce the need for repeat open-heart surgeries. The approval was based on clinical evidence from a pivotal study. Edwards reported that 100 percent of patients were free from device-related complications through 30 days and had no AUTUS valve reinterventions through six months. Patients will continue to be followed for 10 years, the company said in its release.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026. The Lang & Schwarz weekend indication and the October 2 Xetra close remain separate market references.
